Sigyn Therapeutics, Inc. Net Income Loss

• Sigyn Therapeutics, Inc. showed an increase of +19.4% in Net Income Loss from 2023 to 2024.
• This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
• XBRL data for this metric is available from 2014 to 2024 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2014 to 2024), Sigyn Therapeutics, Inc.'s Net Income Loss has declined by 761.9%.
• Historical annual values: Fiscal year 2024: -$3.34 million | Fiscal year 2023: -$4.15 million | Fiscal year 2022: -$2.93 million | Fiscal year 2021: -$3.00 million | Fiscal year 2020: -$1.26 million | Fiscal year 2019: -$3.07 million | Fiscal year 2018: -$2.62 million | Fiscal year 2017: -$4.25 million | Fiscal year 2015: -$2.69 million | Fiscal year 2014: -$387.5 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026